Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase II trial tests whether using genetic testing of tumor tissue to select the optimal treatment regimen works in treating patients with clear cell renal cell (kidney) cancer that has spread to other places in the body (advanced or metastatic). The current Food and Drug Administration (FDA)-approved regimens for advanced kidney cancer fall into two categories. One treatment combination includes two immunotherapy drugs (nivolumab plus ipilimumab), which are delivered by separate intravenous infusions into a vein. The other combination is one immunotherapy drug (nivolumab infusion) plus an oral pill taken by mouth (cabozantinib). Nivolumab and ipilimumab are "immunotherapies" which release the brakes of the immune system, thus allowing the patient's own immune system to better kill cancer cells. Cabozantinib is a "targeted therapy" specifically designed to block certain biological mechanisms needed for growth of cancer cells. In kidney cancer, cabozantinib blocks a tumor's blood supply. The genetic (DNA) makeup of the tumor may affect how well it responds to therapy. Testing the makeup (genes) of the tumor, may help match a treatment (from one of the above two treatment options) to the specific cancer and increase the chance that the disease will respond to treatment. The purpose of this study is to learn if genetic testing of tumor tissue may help doctors select the optimal treatment regimen to which advanced kidney cancer is more likely to respond.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony nowotwór nerek (rak jasnokomórkowy)
- •Zaawansowany lub rozprzestrzeniony rak nerek (stopień IV)
- •Wiek co najmniej 18 lat
- •Ogólny stan zdrowia pozwalający na leczenie (co najmniej 70% na skali wydolności)
- •Brak poprzedniego leczenia systemowego tego nowotworu
- •Dostępna próbka tkanki guza do badania genetycznego
- •Prawidłowa funkcja nerek i wątroby
- •U kobiet w wieku rozrodczym: negatywny test ciąży
✗ Disqualifies
- •Duża operacja chirurgiczna wykonana mniej niż 14 dni przed rozpoczęciem leczenia
- •Niekontrolowane wysokie ciśnienie krwi
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 19, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (6)
City of Hope National Medical Center
Duarte, United States
Chao Family Comprehensive Cancer Center
Orange, United States
University Hospitals Seidman Cancer Center
Cleveland, United States
Cleveland Clinic
Cleveland, United States
Vanderbilt University/Ingram Cancer Center
Nashville, United States
University of Texas, Southwestern Medical Center
Dallas, United States
Trial contact
Vanderbilt-Ingram Service for Timely Access
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/20/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.